%0 Journal Article
%T Corrigendum
%A Channing J Paller
%A Emmanuel S Antonarakis
%J Drug Design, Development and Therapy
%D 2011
%I Dove Medical Press
%R http://dx.doi.org/10.2147/DDDT.S19759
%X Corrigendum Corrigendum (4118) Total Article Views Authors: Channing J Paller, Emmanuel S Antonarakis Published Date March 2011 Volume 2011:5 Pages 183 - 184 DOI: http://dx.doi.org/10.2147/DDDT.S19759 Paller CJ, Antonarakis ES. Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer. Drug Design, Development and Therapy. 2011;5:117¨C124. The drug Jevtana was incorrectly named Jentava in Table 4. Original Article Post to: Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter   Other articles by Dr Emmanuel Antonarakis Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer Readers of this article also read: New atypical antipsychotics for schizophrenia: iloperidone Available and emerging treatments for ParkinsonĄ¯s disease: a review Intercellular cancer collisions generate an ejected crystal comet tail effect with fractal interface embryoid body reassembly transformation Fungus-mediated biological synthesis of gold nanoparticles: potential in detection of liver cancer Preliminary study of highly cross-linked hyaluronic acid-based combination therapy for management of knee osteoarthritis-related pain Short communication: carboxylate functionalized superparamagnetic iron oxide nanoparticles (SPION) for the reduction of S. aureus growth post biofilm formation Gene expression profiles in primary duodenal chick cells following transfection with avian influenza virus H5 DNA plasmid encapsulated in silver nanoparticles Facile one-step coating approach to magnetic submicron particles with poly(ethylene glycol) coats and abundant accessible carboxyl groups Cancer stem cell theory: therapeutic implications for nanomedicine Oral biofilms: molecular analysis, challenges, and future prospects in dental diagnostics
%K Corrigendum Corrigendum (4118) Total Article Views Authors: Channing J Paller
%K Emmanuel S Antonarakis Published Date March 2011 Volume 2011:5 Pages 183 - 184 DOI: http://dx.doi.org/10.2147/DDDT.S19759 Paller CJ
%K Antonarakis ES. Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer. Drug Design
%K Development and Therapy. 2011
%K 5:117¨C124. The drug Jevtana was incorrectly named Jentava in Table 4. Original Article Post to: Cannotea Citeulike Del.icio.us Facebo
%U https://www.dovepress.com/corrigendum-a-novel-second-line-peer-reviewed-article-DDDT